In this study, we demonstrated that Nur77 could inhibit the tumorigenesis and progression of ESCC via the downregulation of IRF1/PD-L1 expression and significantly enhance immunotherapy efficacy in ESCC patients. The gene discussed is NR4A1; the disease is esophageal squamous cell carcinoma.